Skip to Content
MilliporeSigma
All Photos(1)

Documents

A-020

Supelco

Amobarbital solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C11H18N2O3
CAS Number:
57-43-2
Molecular Weight:
226.27
MDL number:
MFCD00057558
UNSPSC Code:
41116107
PubChem Substance ID:
329770580
NACRES:
NA.24

grade

certified reference material

form

liquid

feature

SNAP-N-SPIKE®. SNAP-N-SHOOT®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

drug control

Narcotic Licence Schedule B (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IIC (Portugal)

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

forensics and toxicology

format

single component solution

storage temp.

−20°C

SMILES string

O=C(NC(C1(CC)CCC(C)C)=O)NC1=O

InChI

1S/C11H18N2O3/c1-4-11(6-5-7(2)3)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16)

InChI key

VIROVYVQCGLCII-UHFFFAOYSA-N

Related Categories

General description

A Certified Spiking Solution® for amobarbital testing methods by GC/MS or LC/MS for clinical toxicology, medication monitoring, forensic analysis, pain prescription monitoring, or urine drug testing applications. Amobarbital is a barbiturate approved for treatment of anxiety, insomnia, and epilepsy.

Application



  • Barbiturate biochemical analysis: A study detailed a new approach for the analysis of barbiturates, including amobarbital, using ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS), highlighting advancements in detecting and quantifying these substances in forensic and toxicological contexts (Wachełko et al., 2023).

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes,Central nervous system

Storage Class

3 - Flammable liquids

wgk_germany

WGK 2

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Lindsay A Whitman et al.
Epilepsia, 53(4), 721-727 (2012-02-09)
Despite the reported diagnostic value of the intracarotid amobarbital procedure (IAP) or "Wada test" for determining hemispheric lateralization and memory functioning, it has never undergone formal reliability testing because a prospective test-retest study design is neither feasible nor ethical. However
Propofol, amobarbital… is it the substance that matters, or the question about the role of the Wada test in brain tumor patients?
Karl Schaller
World neurosurgery, 75(3-4), 428-430 (2011-05-24)
Daniel L Drane et al.
Epilepsia, 53(10), 1790-1798 (2012-07-12)
Exclusive right hemisphere language lateralization is rarely observed in the Wada angiography results of epilepsy surgery patients. Cortical stimulation mapping (CSM) is infrequently performed in such patients, as most undergo nondominant left hemisphere resections, which are presumed not to pose
M Zijlmans et al.
Journal of neurology, 259(8), 1632-1638 (2012-01-27)
The purpose of this study was to evaluate the contribution of posterior circulation to memory function by comparing memory scores between patients with and without a foetal-type posterior cerebral artery (FTP) during the intracarotid amobarbital procedure (IAP) in epilepsy patients.
Impact of pretreatment with amobarbital on electroconvulsive therapy outcomes.
Clint Ross et al.
The journal of ECT, 29(1), e10-e11 (2013-02-21)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service